Organization | University of Houston

University of Houston Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Houston TX United States (1927)

Organization Overview

First Clinical Trial

2007

NCT00670267

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

the University of Houston/Memorial HermannHospital, Houston | University of Houston | University of Houston, College of Pharmacy, Houston

Active Ingredients

Drugs in Phase 4 Trials (3)

nicotine (nicorette) (4 trials)

omadacycline (nuzyra) (1 trial)

onabotulinumtoxinA (Botox) (2 trials)

Drugs in Phase 3 Trials (1)

zonisamide (Zonegran) (1 trial)

Drugs in Phase 2 Trials (1)

nadolol (corgard) (1 trial)

Drugs in Phase 1 Trials (1)

ringer's lactate (1 trial)

Drugs in Other Trials (8)

ethanol (1 trial)

fluorouracil (efudex) (1 trial)

irinotecan (Camptosar) (1 trial)

leucovorin (1 trial)

omega-3 fatty acids (Omacor) (2 trials)

raloxifene (evista) (1 trial)

safflower oil (2 trials)

xiaochaihu-tang (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Alcoholism (Phase 3)

Anxiety Disorders (Phase 1)

Asthma (Phase 2)

Depression (Phase 1)

Depressive Disorder (Phase 1)

Disease (Phase 1)

Muscle Spasticity (Phase 4)

Opioid-Related Disorders (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 14
# of Trial APIs: 14